160 related articles for article (PubMed ID: 33987243)
1. A computed tomography (CT)-derived radiomics approach for predicting primary co-mutations involving
Zhu Y; Guo YB; Xu D; Zhang J; Liu ZG; Wu X; Yang XY; Chang DD; Xu M; Yan J; Ke ZF; Feng ST; Liu YL
Ann Transl Med; 2021 Apr; 9(7):545. PubMed ID: 33987243
[TBL] [Abstract][Full Text] [Related]
2. Value of multi-center
Zuo Y; Liu L; Chang C; Yan H; Wang L; Sun D; Ruan M; Lei B; Xia X; Xie W; Song S; Huang G
Med Phys; 2024 Jan; ():. PubMed ID: 38285641
[TBL] [Abstract][Full Text] [Related]
3. Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid Nodule.
Yang X; Dong X; Wang J; Li W; Gu Z; Gao D; Zhong N; Guan Y
Oncologist; 2019 Nov; 24(11):e1156-e1164. PubMed ID: 30936378
[TBL] [Abstract][Full Text] [Related]
4. Dual-energy CT-based radiomics in predicting EGFR mutation status non-invasively in lung adenocarcinoma.
Ma JW; Jiang X; Wang YM; Jiang JM; Miao L; Qi LL; Zhang JX; Wen X; Li JW; Li M; Zhang L
Heliyon; 2024 Jan; 10(2):e24372. PubMed ID: 38304841
[TBL] [Abstract][Full Text] [Related]
5. Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma.
Jiang M; Yang P; Li J; Peng W; Pu X; Chen B; Li J; Wang J; Wu L
Front Oncol; 2022; 12():985284. PubMed ID: 36052262
[TBL] [Abstract][Full Text] [Related]
6. Identifying EGFR mutations in lung adenocarcinoma by noninvasive imaging using radiomics features and random forest modeling.
Jia TY; Xiong JF; Li XY; Yu W; Xu ZY; Cai XW; Ma JC; Ren YC; Larsson R; Zhang J; Zhao J; Fu XL
Eur Radiol; 2019 Sep; 29(9):4742-4750. PubMed ID: 30778717
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
Wang F; Zhao N; Gao G; Deng HB; Wang ZH; Deng LL; Yang Y; Lu C
J Cancer Res Clin Oncol; 2020 Nov; 146(11):2851-2859. PubMed ID: 32743759
[TBL] [Abstract][Full Text] [Related]
8. [Application of radiomics captured from CT to predict the EGFR mutation status and TKIs therapeutic sensitivity of advanced lung adenocarcinoma].
Yang CS; Chen WD; Gong GZ; Li ZJ; Qiu QT; Yin Y
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):282-287. PubMed ID: 31014053
[No Abstract] [Full Text] [Related]
9. Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma.
Yang C; Chen W; Gong G; Li Z; Qiu Q; Yin Y
Transl Cancer Res; 2020 Nov; 9(11):6683-6690. PubMed ID: 35117278
[TBL] [Abstract][Full Text] [Related]
10. [The value of CT radiomics in the prediction of EGFR mutation in lung cancer].
Yu YX; Wang XM; Shi C; Hu S; Hu CH
Zhonghua Yi Xue Za Zhi; 2020 Mar; 100(9):690-695. PubMed ID: 32187913
[No Abstract] [Full Text] [Related]
11. Prognostic Effect of TP53 and PKD Co-Mutations in Patients with Resected Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma.
Liu DH; Zhao ZR; Lin YB; Zhou WJ; Hou JY; Ye ZH; Long H
Ann Surg Oncol; 2019 Jun; 26(6):1934-1941. PubMed ID: 30820786
[TBL] [Abstract][Full Text] [Related]
12. Performance of
Zhang M; Bao Y; Rui W; Shangguan C; Liu J; Xu J; Lin X; Zhang M; Huang X; Zhou Y; Qu Q; Meng H; Qian D; Li B
Front Oncol; 2020; 10():568857. PubMed ID: 33134170
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Identification of
Zhang T; Xu Z; Liu G; Jiang B; de Bock GH; Groen HJM; Vliegenthart R; Xie X
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33920322
[TBL] [Abstract][Full Text] [Related]
15. Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma.
Huo JW; Luo TY; Diao L; Lv FJ; Chen WD; Yu RZ; Li Q
Front Oncol; 2022; 12():846589. PubMed ID: 36059655
[TBL] [Abstract][Full Text] [Related]
16. Identification of risk factors of EGFR-TKIs primary resistance in lung adenocarcinoma patients and construction of a risk predictive model: a case-control study.
Zhang H; Cao C; Xiong H
Transl Cancer Res; 2024 Apr; 13(4):1762-1772. PubMed ID: 38737684
[TBL] [Abstract][Full Text] [Related]
17. The Potential of Radiomics Nomogram in Non-invasively Prediction of Epidermal Growth Factor Receptor Mutation Status and Subtypes in Lung Adenocarcinoma.
Zhao W; Wu Y; Xu Y; Sun Y; Gao P; Tan M; Ma W; Li C; Jin L; Hua Y; Liu J; Li M
Front Oncol; 2019; 9():1485. PubMed ID: 31993370
[No Abstract] [Full Text] [Related]
18. Predicting EGFR mutation subtypes in lung adenocarcinoma using
Liu Q; Sun D; Li N; Kim J; Feng D; Huang G; Wang L; Song S
Transl Lung Cancer Res; 2020 Jun; 9(3):549-562. PubMed ID: 32676319
[TBL] [Abstract][Full Text] [Related]
19. Machine Learning-Based Radiomics for Prediction of Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma.
Lu J; Ji X; Wang L; Jiang Y; Liu X; Ma Z; Ning Y; Dong J; Peng H; Sun F; Guo Z; Ji Y; Xing J; Lu Y; Lu D
Dis Markers; 2022; 2022():2056837. PubMed ID: 35578691
[TBL] [Abstract][Full Text] [Related]
20.
Yang B; Ji HS; Zhou CS; Dong H; Ma L; Ge YQ; Zhu CH; Tian JH; Zhang LJ; Zhu H; Lu GM
Transl Lung Cancer Res; 2020 Jun; 9(3):563-574. PubMed ID: 32676320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
